They can tease out the impact of these factors from the impact of the medications
Food and Drug Administration (FDA) has approved four GLP-1 drugs for weight loss in people with overweight or obesity: liraglutide (Saxenda) orforglipron (Foundayo) semaglutide (Wegovy) tirzepatide (Zepound) Liraglutide, semaglutide, and tirzepatide are injectable medications that come in prefilled pens
An oral liraglutide nanomicelle formulation conferring reduced insulin-resistance and long-term hypoglycemic and lipid metabolic benefits
The seven drugs that are currently considered GLP-1 receptor agonists include: Dulaglutide (Trulicity) Tirzepatide (Mounjaro, Zepbound) Exenatide extended-release (Bydureon) Exenatide (Byetta) Semaglutide injection (Ozempic, Wegovy) Semaglutide tablet (Rybelsus) Liraglutide (Victoza, Saxenda) Lixisenatide (Adlyxin) If all of these drugs influence GLP-1 in similar ways, what makes each of them unique
I always encourage patients to do their research on weight loss [drugs] and lifestyle modifications before the appointment, so they are aware of potential side effects, risks, and benefits of the medication, says Small
